Organogenesis Holdings Inc.

Organogenesis Holdings Inc. (Nasdaq: ORGO) is a regenerative medicine company focused on advanced wound care and surgical biologics that entered the public markets through a SPAC business combination in 2018. Operating in the healthcare sector, the company develops and commercializes a portfolio of products designed to support the body's natural healing processes across both chronic and acute wound care indications. On May 7, 2026, Organogenesis filed an 8-K current report with the SEC under accession number 0001661181-26-000007. For comprehensive filing history, deal terms, and sponsor data on Organogenesis Holdings and hundreds of other SPAC-linked companies, sign up for full access at SpacDesk.